Breaking news

WHO’s Historic Agreement: A Major Step Towards Global Pandemic Preparedness

In a groundbreaking move, members of the World Health Organization (WHO) have reached a historic, legally binding agreement aimed at preparing the world for future pandemics. This pact, designed to address the lessons learned from the COVID-19 crisis, sets the stage for a more equitable global response to health emergencies, particularly in the distribution of essential drugs, vaccines, and medical technologies.

The agreement marks a significant milestone in global health governance, especially at a time when multilateral institutions like the WHO are facing considerable financial strain. The United States, which was once the WHO’s largest financial contributor, withdrew from negotiations after President Donald Trump initiated the U.S.’s departure from the organization. Despite this setback, the deal underscores a strong commitment from member states to work together on global health security, with or without U.S. involvement. “This is a historic moment,” said Nina Schwalbe, founder of global health think tank Spark Street Advisors. “It demonstrates that countries are committed to multilateralism and to collective action.”

This agreement, the second of its kind in WHO’s 75-year history (the first being a tobacco control treaty in 2003), focuses on structural inequalities in how pandemic-related health tools are developed and distributed. Article nine of the deal ensures that future pandemic-related drugs, therapeutics, and vaccines will be made globally accessible. It also gives the WHO stronger oversight over medical supply chains and paves the way for local production of vaccines during health crises.

A key challenge in the negotiations was the issue of technology transfer—sharing the knowledge and manufacturing capabilities necessary for lower-income countries to produce their vaccines and treatments. To address this, the agreement mandates that manufacturers allocate at least 20% of their real-time production to the WHO during a pandemic, with a minimum of 10% designated for donation and the rest priced affordably for developing nations.

The deal is not yet finalized, as it must be adopted at the WHO Assembly in May, and some details, such as the annex on Pathogen Access and Benefit Sharing, still require further negotiation. However, once ratified, the agreement will bolster global preparedness, enabling quicker responses to future pandemics and more equitable access to life-saving resources.

As health experts emphasize, the global community must invest in preparedness now to avoid the costly toll of another pandemic. “We can’t afford another pandemic, but we can afford to prevent one,” said Helen Clark, co-chair of The Independent Panel for Pandemic Preparedness. This agreement represents a critical step toward ensuring that the world is better equipped to face future health crises with solidarity, transparency, and a commitment to equity.

Medochemie And Theramir Announce Strategic Investment Agreement To Advance Biotech Manufacturing In Cyprus

Pharmaceutical manufacturer Medochemie and biotechnology company Theramir, both Cyprus-based, have announced a strategic investment agreement and collaboration aimed at developing next-generation biological therapies and expanding manufacturing capabilities in Cyprus.

The agreement, announced on 2 September 2026, brings together Medochemie’s experience in pharmaceutical manufacturing and Theramir’s biotechnology research. The companies said the collaboration would support advanced pharmaceutical manufacturing in Cyprus and south-eastern Europe.

What The Partnership Covers

Medochemie’s contribution will include its expertise in manufacturing sterile therapeutic products and its access to international markets.

Theramir develops technologies based on extracellular vesicles and microRNAs. Its work includes using stem-cell-derived extracellular vesicles to deliver microRNAs, small, non-coding RNA molecules that regulate genes and biological pathways associated with cancer growth and metastasis.

Under the agreement, the companies will jointly support the development of “Good Manufacturing Practice” capabilities for next-generation biological therapies. The partnership is also intended to help move these therapies towards clinical development.

A Wider Role For Cyprus

The collaboration will also support Theramir’s wider research programme. According to the companies, it is intended to strengthen Cyprus’s biotechnology infrastructure and expand local capacity in next-generation biomanufacturing.

They present the agreement as a step towards giving Cyprus a larger role in biotechnology and advanced pharmaceutical manufacturing for south-eastern Europe and international markets.

Uol
Aretilaw firm
eCredo
The Future Forbes Realty Global Properties

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter